The primary goal of the BU ADC Clinical Core is to provide resources and infrastructure to facilitate clinical research in Alzheimer's disease (AD) and related disorders, such that data and well-characterized research subjects are widely available and shared with other investigators and institutions. During the current funding cycle of the BU ADC, Clinical Core faculty have made major contributions in several important and innovative areas of investigation, which include three general themes: (1) Alzheimer's disease (AD) genetics and genetic risk disclosure;(2) medical and environmental risk factors for cognitive aging;and (3) the longterm effects of repetitive head trauma in the development of neurodegenerative disease. Core faculty have led or participated in several high profile national studies and have facilitated and made possible major breakthroughs in AD-related research both locally and nationally. The longitudinal Patient/Control Registry is now fully subscribed with over 450 active participants and a wide variety of clinical research studies are being actively supported. Over this past cycle, there have been 1374 referrals of registry participants to other studies with 752 enrollments to a total of 38 unique research projects.
The Specific Aims of the Clinical Core for the next five years are:
Specific Aim 1 : To support innovative clinical AD research by identifying, recruiting, and thoroughly characterizing subjects willing to participate in clinical trials and other cutting-edge clinical research studies. We will leverage our resources to promote and accomplish wodd-class AD-related research at BU through our partnerships with the Center for the Study of Traumatic Encephalopathy and the Framingham Heart Study and through our role as a leading site in national NIH and industry supported clinical research.
Specific Aim 2 : To establish research-quality diagnoses on all participants through multidisciplinary diagnostic consensus conferences and to collect and submit high quality data to the Data Management and Statistics Core (DMSC) for timely UDS submissions to the NACC database and for data sharing with qualified AD investigators engaged in cutting edge AD-related research.
Specific Aim 3 : To collect, store, analyze, and distribute biological samples from registry participants for APOE genotyping, DNA banking, and biomarker assays, to support high priority AD-related research.
Specific Aim 4 : To collaborate with the neuropathology and education cores to maximize CNS tissue donation for clinicopathological correlations and for other state of the art tissue-based research.

Public Health Relevance

Alzheimer's disease (AD) and related disorders present a growing public health crisis. The BU ADC Clinical Core provides multiple resources, including well-characterized participants, biospecimens, clinical research data, and expertise to advance our knowledge of the detection, diagnosis, genetics, clinical course, prevention, and treatment of AD and related disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG013846-18
Application #
8501190
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
18
Fiscal Year
2013
Total Cost
$499,717
Indirect Cost
$103,118
Name
Boston University
Department
Type
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Petyuk, Vladislav A; Chang, Rui; Ramirez-Restrepo, Manuel et al. (2018) The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target. Brain 141:2721-2739
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
Chung, Jaeyoon; Wang, Xulong; Maruyama, Toru et al. (2018) Genome-wide association study of Alzheimer's disease endophenotypes at prediagnosis stages. Alzheimers Dement 14:623-633
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416
Christensen, Kurt D; Uhlmann, Wendy R; Roberts, J Scott et al. (2018) A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone. Genet Med 20:132-141
Farrar, Danielle C; Mian, Asim Z; Budson, Andrew E et al. (2018) Functional brain networks involved in decision-making under certain and uncertain conditions. Neuroradiology 60:61-69
Nicolas, Aude (see original citation for additional authors) (2018) Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron 97:1268-1283.e6
Morrison, Filomene G; Miller, Mark W; Wolf, Erika J et al. (2018) Reduced interleukin 1A gene expression in the dorsolateral prefrontal cortex of individuals with PTSD and depression. Neurosci Lett 692:204-209

Showing the most recent 10 out of 791 publications